The subsequent analytical validation phase involves standardizing quantification techniques, including immunohistochemistry for DCK, methylation-specific PCR for BRCA1 and CDH1, and flow cytometry for tumor-infiltrating lymphocyte (TIL) profiling, potentially through multiplexed panels that capture both epigenetic and immune phenotypes. This evidence concerns the gene CDH1 and neoplasm.